IDEAYA Biosciences, Inc. IDYA
We are a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Our clinical development strategy is to evaluate our product candidates in rational combinations, where appropriate, and earlier in the course of disease in the adjuvant and neoadjuvant settings, which we believe has the potential to maximize their impact. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218.7M | $7.0M | $23.4M | $50.9M | $27.9M | $19.5M | $0 | — | — | — |
| R&D | $314.7M | $294.7M | $129.5M | $89.5M | $58.2M | $39.7M | $34.3M | $31.7M | $12.4M | — |
| SG&A | $63.3M | $39.3M | $28.3M | $23.9M | $20.1M | $15.2M | $10.0M | $4.7M | $2.1M | — |
| Total operating expenses | $378.0M | $334.0M | $157.8M | $113.4M | $78.2M | $54.9M | $44.3M | $36.4M | $14.4M | — |
| Operating income | -$159.3M | -$327.0M | -$134.4M | -$62.5M | -$50.3M | -$35.3M | -$44.3M | -$36.4M | -$14.4M | — |
| Pre-tax income | -$113.7M | -$274.5M | -$113.0M | -$58.7M | -$49.8M | -$34.5M | -$42.0M | -$34.3M | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$113.7M | -$274.5M | -$113.0M | -$58.7M | -$49.8M | -$34.5M | -$42.0M | -$34.3M | -$11.9M | — |
| EPS, basic | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 | -1.40 | — | — | — | — |
| EPS, diluted | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 | -1.40 | -3.36 | -35.92 | -17.06 | — |
| Shares, diluted (wtd. avg.) | $88.5M | $81.7M | $57.5M | $41.4M | $35.3M | $24.7M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $112.8M | $84.4M | $157.0M | $68.7M | $92.2M | $72.1M | $34.2M | $20.6M | $6.0M | $9.7M |
| Short-term investments | $526.6M | $591.9M | $368.1M | $296.2M | $154.7M | $211.5M | $64.9M | $69.5M | — | — |
| Receivables | — | $3.0K | $18.0K | $211.0K | $1.1M | $1.9M | — | — | — | — |
| Total current assets | $666.7M | $689.7M | $532.6M | $370.5M | $251.0M | $288.6M | $101.7M | $90.7M | — | — |
| Property, plant and equipment | $8.2M | $9.0M | $6.2M | $6.5M | $4.8M | $4.3M | $4.6M | $5.2M | — | — |
| Total assets | $1.11B | $1.12B | $649.3M | $388.0M | $381.3M | $298.3M | $113.0M | $96.5M | — | — |
| Accounts payable | $17.6M | $15.4M | $6.6M | $4.3M | $2.1M | $953.0K | $709.0K | $1.4M | — | — |
| Total current liabilities | $58.8M | $46.1M | $27.1M | $31.7M | $45.2M | $38.6M | $6.9M | $5.4M | — | — |
| Total liabilities | $86.4M | $64.9M | $28.2M | $38.5M | $79.8M | $100.0M | $12.6M | $7.1M | — | — |
| Retained earnings | -$736.5M | -$622.8M | -$348.4M | -$235.4M | -$176.7M | -$127.0M | -$92.5M | -$50.5M | — | — |
| Total equity | $1.02B | $1.06B | $621.1M | $349.5M | $301.5M | $198.3M | $100.4M | -$48.9M | -$15.7M | -$4.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$71.1M | -$247.6M | -$115.2M | -$87.2M | -$55.8M | $55.5M | -$39.3M | -$27.6M | -$12.2M | — |
| Depreciation and amortisation | $2.7M | $2.4M | $2.5M | $2.1M | $1.7M | $1.4M | $1.2M | $886.0K | $391.0K | — |
| Stock-based compensation | $46.1M | $34.7M | $18.5M | $11.6M | $8.2M | $3.6M | $2.2M | $950.0K | $136.0K | — |
| Capital expenditure | $2.4M | $3.9M | $2.4M | $3.4M | $2.6M | $493.0K | $1.4M | $1.7M | $1.8M | — |
| Investing cash flow | $70.0M | -$502.6M | -$158.5M | -$33.4M | -$69.7M | -$146.2M | $2.3M | -$63.2M | -$8.9M | — |
| Financing cash flow | $29.8M | $677.6M | $362.7M | $97.2M | $145.5M | $128.8M | $50.6M | $105.4M | $17.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-191501.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |